VarmX is a young Leiden based biotech company that is focusing on the development of therapies in the field of hemostasis and thrombosis. Originally a spin-off from the Leiden University Medical Center (LUMC), our mission is to develop and manufacture therapeutic proteins to restore hemostasis. Our lead compound, VMX-C001, is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors.

Research scientist involved in projects involving thrombosis and hemostasis, molecular and cell biology, protein engineering, assay development, structural biology and gene therapy.

PhD thesis focused on the study of macromolecular enzyme-cofactor complexes involved in regulating blood coagulation, with the aim to identifying new therapeutic targets for the treatment of hemostatic disorders.

Appointment as assistant in several Bsc courses involving practicals, including Microbiology, Biological- and Biochemistry, Toxicology and Immunology.

MSc Internship aimed at identifying the role of 14-3-3 protein isotypes in potassium channel regulation in Arabidopsis by yeast two-hybrid.

MSc Internship aimed at investigating bacterial capsular polysaccharide biosynthesis proteins by protein purification and crystallization, in cooperation with the Division of Biological Chemistry and Molecular Microbiology, University of Dundee.